180 Life Sciences Corp.
ATNF
$3.00
$0.8740.85%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -29.50% | 100.14% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -27.08% | 68.73% | |||
| Operating Income | 27.08% | -68.73% | |||
| Income Before Tax | 27.12% | 48.15% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 27.12% | 44.56% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 27.12% | 44.56% | |||
| EBIT | 27.08% | -68.73% | |||
| EBITDA | 27.25% | -69.44% | |||
| EPS Basic | 54.81% | 93.89% | |||
| Normalized Basic EPS | 54.80% | 75.30% | |||
| EPS Diluted | 54.85% | 93.88% | |||
| Normalized Diluted EPS | 54.80% | 75.30% | |||
| Average Basic Shares Outstanding | 61.28% | 215.47% | |||
| Average Diluted Shares Outstanding | 61.28% | 215.47% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||